India, Nov. 9 -- Editas Medicine, Inc. (EDIT) on Monday reported a narrower third-quarter loss as collaboration revenue increased. The gene-editing company also said it remains on track to begin dosing patients in its first clinical trial of EDIT-401 by year-end. Third-Quarter 2026 Financial Results
Net loss attributable to common stockholders narrowed to $23.39 million, or $0.15 per diluted share, from $25.12 million, or $0.28 per diluted share, a year earlier. Lower interest expense related to the sale of future revenues also helped narrow the loss.
Collaboration and other research revenue rose to $10.36 million from $7.54 million, mainly reflecting milestones achieved by a partner. R&D expenses increased to $21.17 million from $19.77 m...